The Sixth Affiliated Hospital, Sun Yat-sen University
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07653685 | |
| Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease | Abdominal Abscess, Crohn disease, Digestive System Diseases, Infections, Suppuration, abscess, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Not stated | 2026-08-04 | NCT07504510 | |
| Real-World Study of IL-23 Inhibitors in Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Not stated | 2026-07-09 | NCT07545317 | |
| IBD Biomarker Discovery and Validation Platform | Crohn disease, Digestive System Diseases, Disease Attributes, Disease Progression, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Not stated | 2026-07-07 | NCT07686406 | |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 4 | 2026-06-09 | NCT07510191 |